246 related articles for article (PubMed ID: 9516939)
1. Heterogeneity of O6-alkylguanine-DNA-alkyltransferase measured by flow cytometric analysis in blood and bone marrow mononuclear cells.
Liu L; Lee K; Schupp J; Koç ON; Gerson SL
Clin Cancer Res; 1998 Feb; 4(2):475-81. PubMed ID: 9516939
[TBL] [Abstract][Full Text] [Related]
2. Effect of O6-benzylguanine on alkylating agent-induced toxicity and mutagenicity. In Chinese hamster ovary cells expressing wild-type and mutant O6-alkylguanine-DNA alkyltransferases.
Cai Y; Wu MH; Xu-Welliver M; Pegg AE; Ludeman SM; Dolan ME
Cancer Res; 2000 Oct; 60(19):5464-9. PubMed ID: 11034089
[TBL] [Abstract][Full Text] [Related]
3. Differential degradation rates of inactivated alkyltransferase in blood mononuclear cells and tumors of patients after treatment with O(6)-benzylguanine.
Liu L; Spiro TP; Qin X; Majka S; Haaga J; Schupp J; Willson JK; Gerson SL
Clin Cancer Res; 2001 Aug; 7(8):2318-24. PubMed ID: 11489807
[TBL] [Abstract][Full Text] [Related]
4. Differential sensitivity of human and mouse alkyltransferase to O6-benzylguanine using a transgenic model.
Liu L; Lee K; Wasan E; Gerson SL
Cancer Res; 1996 Apr; 56(8):1880-5. PubMed ID: 8620508
[TBL] [Abstract][Full Text] [Related]
5. Isolation of human O6-alkylguanine-DNA alkyltransferase mutants highly resistant to inactivation by O6-benzylguanine.
Xu-Welliver M; Kanugula S; Pegg AE
Cancer Res; 1998 May; 58(9):1936-45. PubMed ID: 9581836
[TBL] [Abstract][Full Text] [Related]
6. Determination of the optimal modulatory dose of O6-benzylguanine in patients with surgically resectable tumors.
Dolan ME; Posner M; Karrison T; Radosta J; Steinberg G; Bertucci D; Vujasin L; Ratain MJ
Clin Cancer Res; 2002 Aug; 8(8):2519-23. PubMed ID: 12171878
[TBL] [Abstract][Full Text] [Related]
7. Protection of CHO cells by mutant forms of O6-alkylguanine-DNA alkyltransferase from killing by 1,3-bis-(2-chloroethyl)-1-nitrosourea (BCNU) plus O6-benzylguanine or O6-benzyl-8-oxoguanine.
Loktionova NA; Xu-Welliver M; Crone TM; Kanugula S; Pegg AE
Biochem Pharmacol; 1999 Jul; 58(2):237-44. PubMed ID: 10423163
[TBL] [Abstract][Full Text] [Related]
8. Inactivation of O6-alkylguanine-DNA alkyltransferase by 8-substituted O6-benzylguanine analogs in mice.
Ewesuedo RB; Wilson LR; Friedman HS; Moschel RC; Dolan ME
Cancer Chemother Pharmacol; 2001; 47(1):63-9. PubMed ID: 11221964
[TBL] [Abstract][Full Text] [Related]
9. Point mutations in human O6-alkylguanine-DNA alkyltransferase prevent the sensitization by O6-benzylguanine to killing by N,N'-bis (2-chloroethyl)-N-nitrosourea.
Loktionova NA; Pegg AE
Cancer Res; 1996 Apr; 56(7):1578-83. PubMed ID: 8603405
[TBL] [Abstract][Full Text] [Related]
10. Leukocyte O6-alkylguanine-DNA alkyltransferase from human donors is uniformly sensitive to O6-benzylguanine.
Gerson SL; Schupp J; Liu L; Pegg AE; Srinivasen S
Clin Cancer Res; 1999 Mar; 5(3):521-4. PubMed ID: 10100702
[TBL] [Abstract][Full Text] [Related]
11. Phase I clinical and pharmacological study of O6-benzylguanine followed by carmustine in patients with advanced cancer.
Schilsky RL; Dolan ME; Bertucci D; Ewesuedo RB; Vogelzang NJ; Mani S; Wilson LR; Ratain MJ
Clin Cancer Res; 2000 Aug; 6(8):3025-31. PubMed ID: 10955780
[TBL] [Abstract][Full Text] [Related]
12. Conserved residue lysine165 is essential for the ability of O6-alkylguanine-DNA alkyltransferase to react with O6-benzylguanine.
Xu-Welliver M; Kanugula S; Loktionova NA; Crone TM; Pegg AE
Biochem J; 2000 Apr; 347(Pt 2):527-34. PubMed ID: 10749683
[TBL] [Abstract][Full Text] [Related]
13. Expression of mammalian O6-alkylguanine-DNA alkyltransferase in a cell line sensitive to alkylating agents.
Dolan ME; Norbeck L; Clyde C; Hora NK; Erickson LC; Pegg AE
Carcinogenesis; 1989 Sep; 10(9):1613-9. PubMed ID: 2766456
[TBL] [Abstract][Full Text] [Related]
14. A novel, sensitive assay for O6-methyl- and O6-ethylguanine in DNA, based on repair by the enzyme O6-alkylguanine-DNA-alkyltransferase in competition with an oligonucleotide containing O6-methylguanine.
Souliotis VL; Kyrtopoulos SA
Cancer Res; 1989 Dec; 49(24 Pt 1):6997-7001. PubMed ID: 2684406
[TBL] [Abstract][Full Text] [Related]
15. Alteration of the conserved residue tyrosine-158 to histidine renders human O6-alkylguanine-DNA alkyltransferase insensitive to the inhibitor O6-benzylguanine.
Xu-Welliver M; Leitão J; Kanugula S; Pegg AE
Cancer Res; 1999 Apr; 59(7):1514-9. PubMed ID: 10197622
[TBL] [Abstract][Full Text] [Related]
16. Depletion of O6-alkylguanine-DNA alkyltransferase by O6-benzylguanine in three-dimensional collagen cultures of normal human breast epithelial cells.
Hamdan MA; Guzman RC; Yang J; Beattie C; Mascharack P; Nandi S
Carcinogenesis; 1992 Oct; 13(10):1743-9. PubMed ID: 1423833
[TBL] [Abstract][Full Text] [Related]
17. Specific labeling of O6-alkylguanine-DNA alkyltransferase by reaction with O6-(p-hydroxy[3H]methylbenzyl)guanine.
Ciocco GM; Moschel RC; Chae MY; McLaughlin PJ; Zagon IS; Pegg AE
Cancer Res; 1995 Sep; 55(18):4085-91. PubMed ID: 7664284
[TBL] [Abstract][Full Text] [Related]
18. O6-alkylguanine-DNA alkyltransferase in cutaneous T-cell lymphoma: implications for treatment with alkylating agents.
Dolan ME; McRae BL; Ferries-Rowe E; Belanich M; van Seventer GA; Guitart J; Pezen D; Kuzel TM; Yarosh DB
Clin Cancer Res; 1999 Aug; 5(8):2059-64. PubMed ID: 10473086
[TBL] [Abstract][Full Text] [Related]
19. Modulation of cyclophosphamide activity by O6-alkylguanine-DNA alkyltransferase.
Friedman HS; Pegg AE; Johnson SP; Loktionova NA; Dolan ME; Modrich P; Moschel RC; Struck R; Brent TP; Ludeman S; Bullock N; Kilborn C; Keir S; Dong Q; Bigner DD; Colvin OM
Cancer Chemother Pharmacol; 1999; 43(1):80-5. PubMed ID: 9923545
[TBL] [Abstract][Full Text] [Related]
20. O6-benzylguanine: a clinical trial establishing the biochemical modulatory dose in tumor tissue for alkyltransferase-directed DNA repair.
Spiro TP; Gerson SL; Liu L; Majka S; Haaga J; Hoppel CL; Ingalls ST; Pluda JM; Willson JK
Cancer Res; 1999 May; 59(10):2402-10. PubMed ID: 10344750
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
